These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22858555)

  • 1. Cost-effectiveness of hepatitis A vaccination for adults in Belgium.
    Luyten J; Van de Sande S; de Schrijver K; Van Damme P; Beutels P
    Vaccine; 2012 Sep; 30(42):6070-80. PubMed ID: 22858555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States.
    Rein DB; Hicks KA; Wirth KE; Billah K; Finelli L; Fiore AE; Hoerger TJ; Bell BP; Armstrong GL
    Pediatrics; 2007 Jan; 119(1):e12-21. PubMed ID: 17200237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China.
    Zhuang GH; Pan XJ; Wang XL
    Vaccine; 2008 Aug; 26(35):4608-16. PubMed ID: 18597903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
    Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries.
    Das A
    Hepatology; 1999 Feb; 29(2):548-52. PubMed ID: 9918934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
    Valenzuela MT; Jacobs RJ; Arteaga O; Navarrete MS; Meyerhoff AS; Innis BL
    Vaccine; 2005 Jul; 23(32):4110-9. PubMed ID: 15964479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].
    Pan XJ; Feng YM; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):862-6. PubMed ID: 22967346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States.
    Arguedas MR; Heudebert GR; Fallon MB; Stinnett AA
    Am J Gastroenterol; 2002 Mar; 97(3):721-8. PubMed ID: 11922569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of hepatitis a vaccination in Thailand.
    Teppakdee A; Tangwitoon A; Khemasuwan D; Tangdhanakanond K; Suramaethakul N; Sriratanaban J; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):118-27. PubMed ID: 12118439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility of universal hepatitis A vaccination in Canada.
    Bauch CT; Anonychuk AM; Pham BZ; Gilca V; Duval B; Krahn MD
    Vaccine; 2007 Dec; 25(51):8536-48. PubMed ID: 17996339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context.
    Sartori AM; de Soárez PC; Novaes HM; Amaku M; de Azevedo RS; Moreira RC; Pereira LM; Ximenes RA; Martelli CM
    Vaccine; 2012 Dec; 30(52):7489-97. PubMed ID: 23107593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C.
    Chapko MK; Yee HS; Monto A; Dominitz JA
    Vaccine; 2010 Feb; 28(7):1726-31. PubMed ID: 20044051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A.
    Jacobs RJ; Koff RS; Meyerhoff AS
    Am J Gastroenterol; 2002 Feb; 97(2):427-34. PubMed ID: 11866283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates.
    Jacobs RJ; Rosenthal P; Meyerhoff AS
    Vaccine; 2004 Mar; 22(9-10):1241-8. PubMed ID: 15003653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands).
    Postma MJ; Bos JM; Beutels P; Schilthuis H; van den Hoek JA
    Vaccine; 2004 May; 22(15-16):1862-7. PubMed ID: 15121296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
    Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
    Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of hepatitis immunization for US college students.
    Jacobs RJ; Saab S; Meyerhoff AS
    J Am Coll Health; 2003 May; 51(6):227-36. PubMed ID: 14510025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands.
    Suijkerbuijk AW; Lugnér AK; van Pelt W; Wallinga J; Verhoef LP; de Melker HE; de Wit GA
    Vaccine; 2012 Jul; 30(35):5199-205. PubMed ID: 22721900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluations of hepatitis A vaccination in middle-income countries.
    Suwantika AA; Yegenoglu S; Riewpaiboon A; Tu HA; Postma MJ
    Expert Rev Vaccines; 2013 Dec; 12(12):1479-94. PubMed ID: 24168129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.